Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ3E | ISIN: US18507C1036 | Ticker-Symbol:
NASDAQ
15.05.25 | 16:17
12,030 US-Dollar
-3,45 % -0,430
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARPOINT NEURO INC Chart 1 Jahr
5-Tage-Chart
CLEARPOINT NEURO INC 5-Tage-Chart

Aktuelle News zur CLEARPOINT NEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiClearPoint Neuro targets 15-20 new site activations in 2025 while advancing cell and gene therapy initiatives4
DiClearPoint Neuro Reports Q1 Earnings: Revenue Beat, EPS Miss, Company Affirms FY25 Guidance1
DiClearPoint Neuro, Inc. - 10-Q, Quarterly Report3
DiClearPoint Neuro, Inc.: ClearPoint Neuro Reports First Quarter 2025 Results233Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company")...
► Artikel lesen
DiClearPoint Neuro secures $110M investment2
MoClearPoint Neuro, Inc. Q1 2025 Earnings Preview1
MoClearPoint Neuro sichert sich Finanzierung von bis zu 105 Millionen US-Dollar5
MoClearPoint Neuro secures up to $105 million financing2
CLEARPOINT NEURO Aktie jetzt für 0€ handeln
MoClearPoint Neuro, Inc.: ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing282SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation...
► Artikel lesen
MoClearPoint Neuro, Inc. - 8-K, Current Report3
28.04.ClearPoint Neuro, Inc.: ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism to Include 1.5 T MRI67SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the...
► Artikel lesen
28.04.ClearPoint Neuro expands FDA application for MRI system1
28.04.Clinical Laserthermia Systems, together with its partner ClearPoint Neuro, announces FDA submission to expand the labeling of ClearPoint Prism® to include 1.5 T MRI guidance3
25.04.ClearPoint Neuro launches new navigation software2
25.04.ClearPoint Neuro, Inc.: ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025204SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the...
► Artikel lesen
24.04.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 - Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room198The platform will be showcased at the American Academy of Neurological Surgeons Annual Meeting in Boston on April 25-28, 2025. SOLANA BEACH, CALIFORNIA / ACCESS Newswire / April 24, 2025 / ClearPoint...
► Artikel lesen
01.04.Stifel raises Clearpoint Neuro stock target to $25 on growth potential1
26.02.ClearPoint Neuro, Inc. - 10-K, Annual Report-
26.02.ClearPoint Neuro, Inc.: ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results349Achieved Record Revenue for 2024 and Growth of 31%;Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the...
► Artikel lesen
26.02.ClearPoint Neuro, Inc. - 8-K, Current Report1
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1